Journal of Lipid and Atherosclerosis最新文献

{"title":"Public Awareness of Dyslipidemia Among the Korean Population: A Survey Study.","authors":"Jae Hyun Bae, Eun-Sun Jin, Sung Eun Kim, Shinae Kang, Jong-Young Lee, Minsu Kim, Heung Yong Jin, Min-Jeong Shin, In-Kyung Jeong","doi":"10.12997/jla.2023.12.3.307","DOIUrl":"10.12997/jla.2023.12.3.307","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to assess the level of public awareness regarding dyslipidemia and its management among the Korean population.</p><p><strong>Methods: </strong>We conducted a web- or mobile-based survey study targeting the general population, using various recruitment methods, between July 25, 2022 and August 26, 2022. The questionnaire consisted of 12 questions designed to collect demographic information and evaluate participants' awareness and knowledge about dyslipidemia.</p><p><strong>Results: </strong>In total, 2,882 participants who completed the survey were included in the analysis. Among the participants, a substantial majority (89.1%) were familiar with the concepts of \"good cholesterol\" and \"bad cholesterol,\" while a comparatively lower percentage (just 46.7%) were acquainted with the term \"dyslipidemia.\" Noticeable variations in understanding were observed when examining specific aspects of dyslipidemia management, including diet, exercise, and pharmacotherapy.</p><p><strong>Conclusion: </strong>The results of this survey underscore the significance of enhancing public awareness about dyslipidemia within the context of health literacy, demonstrating the necessity for a more comprehensive approach that includes education and policymaking to effectively manage dyslipidemia.</p>","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"12 3","pages":"307-314"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fa/3c/jla-12-307.PMC10548193.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41135644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Elevated Lipoprotein(a) Levels and Atrial Fibrillation: A Systematic Review.","authors":"Walter Masson,&nbsp;Leandro Barbagelata,&nbsp;Juan P Nogueira,&nbsp;Pablo Corral,&nbsp;Augusto Lavalle-Cobo,&nbsp;Francisco J Romeo","doi":"10.12997/jla.2023.12.3.267","DOIUrl":"10.12997/jla.2023.12.3.267","url":null,"abstract":"<p><strong>Objective: </strong>The role of lipoprotein(a) (Lp[a]) as a possibly causal risk factor for atherosclerotic cardiovascular disease has been well established. However, the clinical evidence regarding the association between Lp(a) levels and atrial fibrillation (AF) remains limited and inconsistent. This study aimed to analyze the association between elevated Lp(a) levels or single-nucleotide polymorphisms (SNPs) related to high levels of Lp(a) and AF.</p><p><strong>Methods: </strong>This systematic review was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. A literature search was performed to identify studies that evaluated the association between Lp(a) levels or SNPs related to high levels of Lp(a) and AF. Observational studies with a cross-sectional, case-control, or cohort design were included in this systematic review, without limitations according to language, country, or publication type.</p><p><strong>Results: </strong>Eleven observational studies including 1,246,817 patients were eligible for this systematic review. Two cross-sectional studies, 5 prospective/retrospective cohort studies, and 4 Mendelian randomization studies were analyzed. Two cross-sectional studies that compared Lp(a) levels between patients with and without AF showed conflicting results. Cohort studies that evaluated the incidence of AF according to Lp(a) levels showed different results: no association (3 studies), a positive association (1 study), and an inverse relationship (1 study). Finally, Mendelian randomization studies also showed heterogeneous results (positive association: 2 studies; inverse association: 1 study; no association: 1 study).</p><p><strong>Conclusion: </strong>Although there could be an association between Lp(a) levels and AF, the results of the studies published to date are contradictory and not yet definitive. Therefore, further research should clarify this issue.</p>","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"12 3","pages":"267-276"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c7/9b/jla-12-267.PMC10548189.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41119765","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metformin Reduces the Progression of Atherogenesis by Regulating the Sestrin2-mTOR Pathway in Obese and Diabetic Rats.","authors":"Saravanakumar Sundararajan,&nbsp;Isaivani Jayachandran,&nbsp;Gautam Kumar Pandey,&nbsp;Saravanakumar Venkatesan,&nbsp;Anusha Rajagopal,&nbsp;Kuppan Gokulakrishnan,&nbsp;Muthuswamy Balasubramanyam,&nbsp;Viswanathan Mohan,&nbsp;Nagaraj Manickam","doi":"10.12997/jla.2023.12.3.290","DOIUrl":"10.12997/jla.2023.12.3.290","url":null,"abstract":"<p><strong>Objective: </strong>In previous research, we found that Sestrin2 has a strong association with plasma atherogenicity and combats the progression of atherogenesis by regulating the AMPK-mTOR pathway. Metformin, an activator of AMPK, is widely used as a first-line therapy for diabetes, but its role in preventing atherosclerosis and cardiac outcomes is unclear. Hence, we aimed to assess the effect of metformin on preventing atherosclerosis and its regulatory role in the Sestrin2-AMPK -mTOR pathway in obese/diabetic rats.</p><p><strong>Methods: </strong>Animals were fed a high-fat diet to induce obesity, administered streptozotocin to induce diabetes, and then treated with metformin (150 mg/kg body weight) for 14 weeks. Aorta and heart tissues were analyzed for Sestrin2 status by western blotting and immunohistochemistry, AMPK and mTOR activities were investigated using western blotting, and atherogenicity-related events were evaluated using reverse transcription quantitative polymerase chain reaction and histology.</p><p><strong>Results: </strong>Obese and diabetic rats showed significant decrease in Sestrin2 levels and AMPK activity, accompanied by increased mTOR activity in the heart and aorta tissues. Metformin treatment significantly restored Sestrin2 and AMPK levels, reduced mTOR activity, and restored the altered expression of inflammatory markers and adhesion molecules in obese and diabetic rats to normal levels. A histological analysis of samples from obese and diabetic rats showed atherosclerotic lesions both in aorta and heart tissues. The metformin-treated rats showed a decrease in atherosclerotic lesions, cardiac hypertrophy, and cardiomyocyte degeneration.</p><p><strong>Conclusion: </strong>This study presents further insights into the beneficial effects of metformin and its protective role against atherosclerosis through regulation of the Sestrin2-AMPK-mTOR pathway.</p>","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"12 3","pages":"290-306"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/20/b6/jla-12-290.PMC10548184.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41128098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vegetarian Diets and Cardiovascular Risk Reduction: Pros.","authors":"Soo Yong Lee","doi":"10.12997/jla.2023.12.3.315","DOIUrl":"10.12997/jla.2023.12.3.315","url":null,"abstract":"<p><p>There is an ongoing need for public health interventions aimed at further mitigating the risk of cardiovascular disease (CVD) through changes in dietary patterns and other lifestyle habits. Plant-based diets (PBDs) are effective in reducing CVD risk factors, a benefit evidenced by the favorable cardio-metabolic profiles observed in vegetarians who abstain from consuming meat, fish, and poultry compared to omnivores. Numerous studies have demonstrated that PBDs, particularly when rich in high-quality plant foods such as whole grains, fruits, vegetables, and nuts, are associated with a lower risk of adverse cardiovascular outcomes. Herein, we briefly review the current evidence regarding the relationship between CVD and PBDs, as well as the potential underlying biological mechanisms.</p>","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"12 3","pages":"315-322"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e4/3d/jla-12-315.PMC10548187.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41163689","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dyslipidemia Fact Sheet in South Korea, 2022.","authors":"Eun-Sun Jin,&nbsp;Jee-Seon Shim,&nbsp;Sung Eun Kim,&nbsp;Jae Hyun Bae,&nbsp;Shinae Kang,&nbsp;Jong Chul Won,&nbsp;Min-Jeong Shin,&nbsp;Heung Yong Jin,&nbsp;Jenny Moon,&nbsp;Hokyou Lee,&nbsp;Hyeon Chang Kim,&nbsp;In-Kyung Jeong","doi":"10.12997/jla.2023.12.3.237","DOIUrl":"10.12997/jla.2023.12.3.237","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to investigate the prevalence and status of dyslipidemia management among South Korean adults, as performed by the Korean Society of Lipid and Atherosclerosis under the name Dyslipidemia Fact Sheet 2022.</p><p><strong>Methods: </strong>We analyzed the lipid profiles, age-standardized and crude prevalence, management status of hypercholesterolemia and dyslipidemia, and health behaviors among Korean adults aged ≥20 years, using the Korea National Health and Nutrition Examination Survey data between 2007 and 2020.</p><p><strong>Results: </strong>In South Korea, the crude prevalence of hypercholesterolemia (total cholesterol ≥240 mg/dL or use of a lipid-lowering drug) in 2020 was 24%, and the age-standardized prevalence of hypercholesterolemia more than doubled from 2007 to 2020. The crude treatment rate was 55.2%, and the control rate was 47.7%. The crude prevalence of dyslipidemia (more than one out of three conditions [low-density lipoprotein-cholesterol ≥160 or the use of a lipid-lowering drug, triglycerides ≥200, or high-density lipoprotein-cholesterol (men and women) <40 mg/dL]) was 40.2% between 2016 and 2020. However, it increased to 48.2% when the definition of hypo-high-density lipoprotein-cholesterolemia in women changed from <40 to <50 mg/dL.</p><p><strong>Conclusion: </strong>Although the prevalence of hypercholesterolemia and dyslipidemia has steadily increased in South Korea, the treatment rate remains low. Therefore, continuous efforts are needed to manage dyslipidemia through cooperation between the national healthcare system, patients, and healthcare providers.</p>","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"12 3","pages":"237-251"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f9/2b/jla-12-237.PMC10548191.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41123313","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Are Only <i>p</i>-Values Less Than 0.05 Significant? A <i>p</i>-Value Greater Than 0.05 Is Also Significant!","authors":"Sanggyu Kwak","doi":"10.12997/jla.2023.12.2.89","DOIUrl":"https://doi.org/10.12997/jla.2023.12.2.89","url":null,"abstract":"<p><p>Statistical hypothesis testing compares the significance probability value and the significance level value to determine whether or not to reject the null hypothesis. This concludes \"significant or not significant.\" However, since this process is a process of statistical hypothesis testing, the conclusion of \"statistically significant or not statistically significant\" is more appropriate than the conclusion of \"significant or not significant.\" Also, in many studies, the significance level is set to 0.05 to compare with the significance probability value, <i>p</i>-value. If the <i>p</i>-value is less than 0.05, it is judged as \"significant,\" and if the <i>p</i>-value is greater than 0.05, it is judged as \"not significant.\" However, since the significance probability is a value set by the researcher according to the circumstances of each study, it does not necessarily have to be 0.05. In a statistical hypothesis test, the conclusion depends on the setting of the significance level value, so the researcher must carefully set the significance level value. In this study, the stages of statistical hypothesis testing were examined in detail, and the exact conclusions accordingly and the contents that should be considered carefully when interpreting them were mentioned with emphasis on statistical hypothesis testing and significance level. In 11 original articles published in the <i>Journal of Lipid and Atherosclerosis</i> in 2022, the interpretation of hypothesis testing and the contents of the described conclusions were reviewed from the perspective of statistical hypothesis testing and significance level, and the content that I would like to be supplemented was mentioned.</p>","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"12 2","pages":"89-95"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b2/88/jla-12-89.PMC10232224.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9621356","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Autophagy Enhancers Regulate Cholesterol-Induced Cytokine Secretion and Cytotoxicity in Macrophages.","authors":"Su Kyoung Lee,&nbsp;Eun Hee Kam,&nbsp;So Yeong Cheon","doi":"10.12997/jla.2023.12.2.189","DOIUrl":"https://doi.org/10.12997/jla.2023.12.2.189","url":null,"abstract":"<p><strong>Objective: </strong>Hypercholesterolaemia transforms macrophages into lipid-laden foam cells in circulation, which can activate the immune response. Compromised autophagy and inflammatory cytokines are involved in the pathogenesis and progression of metabolic diseases. The aim of this study was to identify the role of autophagy as a modulator of the inflammatory response and cytotoxicity in macrophages under hypercholesterolaemic conditions.</p><p><strong>Methods: </strong>High cholesterol-induced cytokine secretion and alteration of autophagy-associated molecules were confirmed by cytokine array and western blot analysis, respectively. To confirm whether autophagic regulation affects high cholesterol-induced cytokine release and cytotoxicity, protein levels of autophagic molecules, cell viability, and cytotoxicity were measured in cultured macrophages treated autophagy enhancers.</p><p><strong>Results: </strong>Cholesterol treatment increased cytokine secretion, cellular toxicity, and lactate dehydrogenase release in lipopolysaccharide (LPS)-primed macrophages. Concomitantly, altered levels of autophagy-related molecules were detected in LPS-primed macrophages under hypercholesterolaemic conditions. Treatment with autophagy enhancers reversed the secretion of cytokines, abnormally expressed autophagy-associated molecules, and cytotoxicity of LPS-primed macrophages.</p><p><strong>Conclusion: </strong>Autophagy enhancers inhibit inflammatory cytokine secretion and reduce cytotoxicity under metabolic disturbances, such as hypercholesterolaemia. Modulation of autophagy may be a novel approach to control the inflammatory response observed in metabolic diseases.</p>","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"12 2","pages":"189-200"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c2/a5/jla-12-189.PMC10232223.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9621357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Comparison of the Associations of Lipoprotein(a) and the Atherogenic Index of Plasma With Coronary Artery Calcification in Patients Without High LDL-C: A Comparative Analysis.","authors":"Seung-Pyo Hong, Chang-Yeon Kim, Hae Won Jung","doi":"10.12997/jla.2023.12.2.152","DOIUrl":"10.12997/jla.2023.12.2.152","url":null,"abstract":"<p><strong>Objective: </strong>Lipoprotein(a) (Lp[a]) and the atherogenic index of plasma (AIP) have been reported as predictive markers of coronary artery calcium (CAC). However, previous studies demonstrated that the cardiovascular risk associations with Lp(a) are attenuated in patients with low-density lipoprotein cholesterol (LDL-C) levels ≤135 mg/dL. However, few articles have identified the risk factors of CAC in patients without high LDL-C. Therefore, we performed this study to investigate the association of Lp(a) and AIP with CAC in patients with LDL-C levels ≤135 mg/dL.</p><p><strong>Methods: </strong>This study included 625 lipid-lowering agent naive patients with LDL-C levels ≤135 mg/dL who underwent coronary computed tomographic angiography. We performed multivariate logistic regression analysis to evaluate the risk factors for a coronary artery calcium score (CACS) >0, CACS ≥400, and CAC ≥90th percentile.</p><p><strong>Results: </strong>The mean age of the patients was 55.0±7.9 years and their mean LDL-C level was 94.7 ±23.3 mg/dL. Multivariate regression analysis showed that age, male sex, diabetes, hypertension, Lp(a), and AIP were independent predictors of CAS>0. Age, male sex, and diabetes were independent predictors of CACS≥400. Diabetes, hypertension, and AIP were independent predictors of CAC ≥90th percentile (all <i>p</i><0.05). Unlike Lp(a), higher AIP tertiles were associated with significantly higher CAC percentiles and greater proportions of patients with CACS ≥400 and CAC ≥90th percentile.</p><p><strong>Conclusion: </strong>In patients without high LDL-C, AIP could be a more reliable predictor of CAC than Lp(a).</p>","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"12 2","pages":"152-163"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e6/a7/jla-12-152.PMC10232225.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9923672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Low-Density Lipoprotein Cholesterol Levels Are Associated With Subsequent Stented-Territory Ischemic Stroke After Carotid Artery Stenting: A Single Center Retrospective Study.","authors":"Seung Min Kim,&nbsp;Jae Chan Ryu,&nbsp;Sujin Koo,&nbsp;Jong S Kim,&nbsp;Bum Joon Kim","doi":"10.12997/jla.2023.12.2.175","DOIUrl":"https://doi.org/10.12997/jla.2023.12.2.175","url":null,"abstract":"<p><strong>Objective: </strong>The role of low-density lipoprotein cholesterol (LDL-C) after carotid artery stenting (CAS) is not well known with respect to stented-territory infarction (STI) and in-stent restenosis (ISR). We hypothesized that LDL-C levels after CAS might be independently associated with STI and ISR.</p><p><strong>Methods: </strong>We conducted a retrospective study for patients with significant extracranial carotid stenosis who were subjected to CAS between September 2013 and May 2021. LDL-C levels were measured after 6 and 12 months following CAS. The association between STI and ISR, and LDL-C was explored using Cox proportional-hazard model.</p><p><strong>Results: </strong>Of 244 patients enrolled, STI and ISR were observed in 11 (4.5%) and 10 (4.1%) patients, respectively. In multivariable analysis, higher white blood cell count (hazard ratio [HR], 1.408 per 10³/mm³; 95% confidence interval [CI], 1.085-1.828; <i>p</i>=0.010), higher LDL-C levels after 12 months (HR, 1.037 per 1 mg/dL; 95% CI, 1.011-1.063; <i>p</i>=0.005), and ISR (HR, 13.526; 95% CI, 3.405-53.725; <i>p</i><0.001) were independent predictors of STI. Diabetes (HR, 4.746; 95% CI, 1.026-21.948; <i>p</i>=0.046), smaller stent diameter (HR, 0.725 per 1 mm; 95% CI, 0.537-0.980; <i>p</i>=0.036), and higher LDL-C levels after 12 months (HR, 1.031 per 1 mg/dL; 95% CI, 1.007-1.055; <i>p</i>=0.011) were independent predictors of ISR.</p><p><strong>Conclusion: </strong>We showed that LDL-C levels after 12 months independently predict STI and ISR after CAS. It is necessary to investigate the optimal target LDL-C level for STI prevention through well designed research in the future.</p>","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"12 2","pages":"175-188"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3b/ca/jla-12-175.PMC10232219.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9621362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in Prevalence of Hypertriglyceridemia and Related Factors in Korean Adults: A Serial Cross-Sectional Study.","authors":"Kye-Yeung Park, Sangmo Hong, Kyung-Soo Kim, Kyungdo Han, Cheol-Young Park","doi":"10.12997/jla.2023.12.2.201","DOIUrl":"10.12997/jla.2023.12.2.201","url":null,"abstract":"<p><strong>Objective: </strong>We aimed to investigate the longitudinal trends in prevalence of hypertriglyceridemia in Korean adults and hypertriglyceridemia-associated lifestyle habits, socioeconomic factors and comorbidities.</p><p><strong>Methods: </strong>Data from the 2007-2020 Korea National Health and Nutrition Examination Survey (KNHANES) were used in this study. Two cutoff values (≥150 mg/dL and ≥200 mg/dL) for fasting serum triglyceride levels were used to estimate the age- and sex-specific prevalence of hypertriglyceridemia. Use of lipid-lowering medications, lifestyle factors such as smoking, alcohol consumption, and regular exercise, socioeconomic variables such as educational attainment and household income, and comorbidities such as obesity, abdominal obesity, hypertension, and diabetes mellitus were also investigated.</p><p><strong>Results: </strong>The prevalence of hypertriglyceridemia among Koreans based on KNHANES 2007-2020 was 29.6% at ≥150 mg/dL and 16.1% at ≥200 mg/dL. While the rate of using lipid-lowering medications increased steadily from 2007 to 2020, changes in annual prevalence of hypertriglyceridemia were subtle. The prevalence of hypertriglyceridemia in men peaked in middle age (47.7% and 30.0% for ≥150 mg/dL and ≥200 mg/dL, respectively, in their 40s), but its prevalence in women increased throughout their lifetime (32.6% and 14.7% for ≥150 mg/dL and ≥200 mg/dL, respectively, in their 70s). Smoking and high-risk drinking exacerbated peak prevalence in both sexes. Young adults with any comorbidities had prominently increased prevalence of hypertriglyceridemia. The lowest levels of education and income were both associated with the higher prevalence of hypertriglyceridemia in both sexes.</p><p><strong>Conclusion: </strong>It is important to understand the age- and sex-specific epidemiology of hypertriglyceridemia to establish its appropriate management plans.</p>","PeriodicalId":16284,"journal":{"name":"Journal of Lipid and Atherosclerosis","volume":"12 2","pages":"201-212"},"PeriodicalIF":0.0,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/fc/08/jla-12-201.PMC10232222.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9940021","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}